all report title image
  • Published On : Nov 2021
  • Code : CMI4551
  • Industry : Pharmaceutical
  • Pages : 250
  • Formats :

When anticoagulant therapy needs to be reversed or neutralised due to bleeding problems, an overdose of anticoagulant therapy, or unexpected surgery, anticoagulant reversal drugs are required. Anticoagulant reversal is a key step in the treatment of patients who are taking an anticoagulant and are experiencing life-threatening bleeding. The reversal medications recommended by doctors are determined by the patient's anticoagulant of choice. Direct oral anticoagulants (DOACs) consists of dabigatran etexilate, a direct thrombin inhibitor, and specific inhibitors of stimulated coagulation factor X (apixaban, betrixaban, edoxaban, and rivaroxaban). DOACs are linked with lower rates of main and serious bleeding events compared with warfarin. In an emergency situation, clinicians need to attain rapid reversal of anticoagulation effects of the DOACs. Idarucizumab and andexanet alfa, which reverse the anticoagulant effects of dabigatran and FXa inhibitors are DOAC reversal drugs.

The global anticoagulant reversal drugs market is estimated to be valued at US$ 861.6 million in 2021 and is expected to exhibit a CAGR of 14.9% during the forecast period (2021-2028)

Figure 1. Global Anticoagulant Reversal Drugs Market Share (%) in Terms of Value, By Product Type, 2021

Anticoagulant Reversal Drugs  | Coherent Market Insights

Key players operating in the global anticoagulant reversal drugs market are focusing on acquisitions and mergers, which is expected to drive the market growth.

Increasing acquisition provides the opportunity to expand commercial range of anticoagulant reversal drugs, which is expected to drive the market growth during the forecast period. For instance, in May 2020, Alexion Pharmaceuticals, Inc. announced acquisition of Portola Pharmaceuticals, Inc. The acquisition includes Andexx [coagulation factor Xa (recombinant), inactivated-zhzo], branded as Ondexxya, a Factor Xa inhibitor reversal medication. Alexion Pharmaceuticals, Inc. acquired Portola through a tender offer and subsequent merger with Odyssey Merger Sub Inc. Near-term diversification will be added by this acquisition to Alexion’s commercial portfolio.

CMI table icon

Anticoagulant Reversal Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 861.6 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 14.9% 2028 Value Projection: US$ 2,282.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Idarucizumab, Protamine, Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Others
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:

Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy's Laboratories, AMAG Pharmaceuticals, Inc., Pfizer, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., Fresenius Kabi AG, Mundipharma International Limited, and Hisamitsu Pharmaceutical Co., Inc

Growth Drivers:
  • Increasing focus on acquisitions and mergers
  • Increasing requirement of anticoagulants for blood-related disorders in case of uncontrolled bleeding
Restraints & Challenges:
  • High cost of anticoagulant reversal drugs

Figure 2. Global Anticoagulant Reversal Drugs Market Share (%), By Distribution Channel, 2021

Anticoagulant Reversal Drugs  | Coherent Market Insights

Increasing requirement of anticoagulants for blood-related disorders boost the demand for anticoagulant reversal drugs in case of uncontrolled bleeding, which is anticipated to drive the market growth.

Increasing demand for anticoagulant reversal drugs in case of uncontrolled bleeding is expected to drive the market growth during the forecast period. Some of the common bleeding disorders include blood clots, Von Willebrand disease, and hemophilia A and B. One out of 100 individuals are affected by Von Willebrand disease as it is a very common bleeding disorder. Bleeding disorders can cause undesirable bleeding from the patient’s body as well as affect blood clotting. For instance, there are around 30,000 to 33,000 people in the U.S. who are suffering from hemophilia and approximately 60% of them are suffering from acute hemophilia, according to the National Hemophilia Foundation (NHF).

Global Anticoagulant Reversal Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

The unanticipated COVID-19 epidemic had a significant beneficial influence on anticoagulant reversal medicines, with an increase in the number of research and development efforts focused primarily on COVID-19 infection. For instance, about ten clinical trials are now underway to assess the efficacy of factor Xa inhibitors in COVID-19 patients, as revealed by a paper published in the American Journal of Cardiovascular Drugs, in 2020. The development of methods for the parenteral delivery of these medicines that are useful in the treatment of severe COVID-19 patients. As a result, the COVID-19 pandemic will drive the global anticoagulant medication market throughout the projection period.

Global Anticoagulant Reversal Drugs Market: Restraint

The high cost of anticoagulant reversal drugs is one of the restraining factor that is expected to hinder the market growth during the forecast period. 4-F PCC (Kcentra) supports in treating bleeding cases due to apixaban and rivaroxaban and it is administered at 50 units/k, according to the American College of Cardiology. Its average wholesale price is US$ 2.90 per unit, thus treating a patient whose weight is 100 kg that cost about US$ 14,500.

Key Players

Major players operating in the global anticoagulant reversal drugs market include Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy's Laboratories, AMAG Pharmaceuticals, Inc., Pfizer, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., Fresenius Kabi AG, Mundipharma International Limited, and Hisamitsu Pharmaceutical Co., Inc.

Anticoagulation drug therapy is prescribed in patients who are suffering from a venous atrial fibrillation (AF), thromboembolism, mechanical valve replacement, and other coagulation disorders such as antiphospholipid antibody syndrome and Factor V Leiden. In some instances, such as unexpected surgery or anticoagulant overdose, anticoagulant reversal drugs are necessary to reverse the impact of anticoagulation. Increased frequency of cerebral & gastrointestinal haemorrhage and new technology add-on status (NTAP) granted to certain medicines, which focuses on the development of specialised drugs for anticoagulation reversal. Fresh frozen plasma is frequently used to counteract the effects of warfarin, although complete reversal takes six to 24 hours. Prothrombin complex concentrates (PCCs) can be utilised in more urgent situations since they give full anticoagulation reversal in 15-20 minutes.

Several reversal medicines have been developed for patients using newer oral anticoagulants. However, it should be emphasised that these newer anticoagulants have short half-lives (5-17 hours), and reversal is rarely indicated. Reversal medicines have a risk of life-threatening thrombosis and should be used only under the supervision of a professional with experience in their usage and/or in a patient who is at urgent danger of death from bleeding. In most cases, a single dosage is administered. However, dosing may be repeated in exceptional cases when the oral anticoagulant remains in the blood for a prolonged period of time, such as severe renal failure.

Market Dynamics

Increasing spending in research and development is anticipated to propel the anticoagulant reversal drugs market growth during the forecast period. For instance, in December 2020, Octa Pharma USA released the findings of clinical study conducted to assess the safety and efficacy of fibryga, a Human Fibrinogen Lyophilized Powder for Reconstitution recommended for intravenous use in the treatment of congenital and acquired bleeding disorders, in the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

Key features of the study:

  • This report provides an in-depth analysis of the global anticoagulant reversal drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global anticoagulant reversal drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy's Laboratories, AMAG Pharmaceuticals, Inc., Pfizer, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., Fresenius Kabi AG, Mundipharma International Limited, and Hisamitsu Pharmaceutical Co., Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global anticoagulant reversal drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global anticoagulant reversal drugs market

Detailed Segmentation:

  • Global Anticoagulant Reversal Drugs Market, By Product Type:
    • Idarucizumab
    • Protamine
    • Prothrombin Complex Concentrates
    • Phytonadione
    • Andexanet Alfa
    • Others
  • Global Anticoagulant Reversal Drugs Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Anticoagulant Reversal Drugs Market, By Region:
    • North America
      • By Product Type
        • Idarucizumab
        • Protamine
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Product Type
        • Idarucizumab
        • Protamine
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type
        • Idarucizumab
        • Protamine
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type
        • Idarucizumab
        • Protamine
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type
        • Idarucizumab
        • Protamine
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type
        • Idarucizumab
        • Protamine
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Portola Pharmaceuticals *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Boehringer Ingelheim
    • CSL Behring
    • Bausch Health Companies Inc.
    • Octapharma AG
    • Reddy's Laboratories
    • AMAG Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • SGPharma Pvt. Ltd.
    • Alps Pharmaceutical Ind. Co., Ltd.
    • Fresenius Kabi AG
    • Mundipharma International Limited
    • Hisamitsu Pharmaceutical Co., Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global anticoagulant reversal drugs market is estimated to be valued at US$ 861.6 million in 2021 and is expected to exhibit a CAGR of 14.9% between 2021 and 2028.
Factors such as rising number of bleeding disorders is expected to drive the market growth during the forecast period.
Idarucizumab segment expected to hold the major market share during the forecast period.
Major factor hampering the growth of market include high cost of anticoagulant reversal agents.
Major players operating in the market include Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy's Laboratories, AMAG Pharmaceuticals, Inc., Pfizer, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., Fresenius Kabi AG, Mundipharma International Limited, and Hisamitsu Pharmaceutical Co., Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo